42results about How to "Easy and accurate diagnosis" patented technology

The invention relates to a method for diagnosing faults in a high-pressure common rail system of an engine, which comprises the following steps of: breaking at least one cylinder in an engine by adopting a cylinder separation technology; measuring the rail pressure in the high-pressure common rail system after cylinder breakage on the basis of a crankshaft rotating angle; filtering practical rail pressure measured in real time to form input rail pressure; sampling the input rail pressure at a predefined crankshaft rotating angle interval to form a sampling signal; selecting the sampling signal positioned in a rail pressure stable area of the high-pressure common rail system as a characteristic sampling point of rail pressure; filtering the characteristic sampling point to generate rail pressure obtained after cylinder breakage; solving a rail pressure difference value of the rail pressure obtained after cylinder breakage and factory rail pressure; and when the difference value is higher than a preset threshold value, judging that the high-pressure common rail system has a fault. The method also comprises the step of compensating oil spray amount and oil pumping amount which are associated with the rail pressure difference value into the factory oil spray amount and oil pumping amount if the high-pressure common rail system has the fault so as to calibrate the fault.

The invention relates to a residual network rolling bearing fault diagnosis method based on time-frequency analysis. The method comprises the following steps of S1. collecting vibration signal data, converting a vibration time domain signal of a rolling bearing into a time-frequency map by using short-time Fourier transform, and converting the time-frequency map into a two-dimensional gray level time-frequency map; and S2. performing feature extraction on the signal by using a residual network, and diagnosing a fault type of the bearing, wherein the input of the residual network is the gray level time-frequency map generated in the step S1, and the output of the residual network is a fault diagnosis result. According to the residual network rolling bearing fault diagnosis method provided by the invention, the bearing vibration data are converted into the time-frequency map by using the short-time Fourier transform, the time domain and frequency domain features during the vibration of afaulty bearing can be clearly reflected, and the network can accurately diagnose different fault types conveniently. Since the time-frequency signal contains both the time domain and frequency domaininformation of the bearing, and the deepening of a network layer of the residual network does not cause the problem of gradient disappearance or gradient explosion, higher accuracy can be obtained bythe method while performing fault diagnosis on the bearing.

The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and / or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

The invention discloses a crop disease spore capturing, separating and detecting device. The crop disease spore capturing, separating and detecting device comprises a collecting box, an electric control box, a sampling opening and a capturing channel, wherein the sampling opening for introducing disease spores is formed in the upper surface of the collecting box; the bottom of the collecting box is communicated with the capturing channel; a collecting adhesive tape for capturing the spores is arranged in the capturing channel; the collecting adhesive tape is driven by electric wheels at two ends to transmit; the electric control box is arranged on the right side of the collecting box and the capturing channel; a fan, an electric control module of the electric wheels and a microscopic imagecollecting module are arranged in the electric control box; the fan is arranged on the side wall of a box body of the collecting box and the capturing channel; and a directional air source is generated to drive the spores in the collecting box to be uniformly separated and settled to the collecting adhesive tape. The device separates the spores captured in the collecting box, so that the spores are uniformly settled to the collecting adhesive tape with a hollow design, and mutual stacking of collected materials is avoided; and by the advantages of small size, light weight and the like, the crop disease spore capturing, separating and detecting device can be mounted under an unmanned aerial vehicle, a large space monitoring range is covered, and the application prospect is wide.

The invention discloses self-detecting fitness equipment for the health of old people. The fitness equipment comprises a fitness equipment body, the top of the fitness equipment body is provided with an article linking device, a memory device and an open-sourcing single chip microcomputer, a hanger is fixed on the inner side of the fitness equipment body, a neck fixing device is hanged on the hanger, a detecting device is installed on the inner side of the neck fixing device, the input end of the open-sourcing single chip microcomputer is connected with the output end of an external power source, the memory device comprises a memorizer, and the memorizer is installed at the top of the fitness equipment body. The self-detecting fitness equipment for the health of the old people can be used for detecting the health of the old people through the detecting device, timely treatment can be conveniently performed on the old people, meanwhile, the old people can conveniently and scientifically make a plan for exercise time as well, the fitness effect is greatly improved, the information detected by the detection device is stored by the memory device, and the state of an illness of a patient can be accurately diagnosed by a medical worker according to detection information.

The invention discloses a glioma diagnosis and prognosis marker circ16:85633914|85634132 and application. A reagent for detecting annular RNAcirc16:85633914|85634132 sourced from brain tissues is usedfor preparing a diagnosis and prognosis preparation of glioma patients. The research shows that the expression of the RNA circ16:85633914|85634132 in the brain tissues of the glioma patient is apparently reduced compared with the normal brain tissues, and the ROC curve analysis shows that the RNA circ16:85633914|85634132 has relatively high diagnosis performance for the glioma. Meanwhile, the patient with relatively high expression of the circ16:85633914|85634132 has higher post-operative survival rate. The diagnosis analysis and prognosis determination can be made for the glioma high risk group by detecting the annular RNA circ16:85633914|85634132 in the glioma tissues of the glioma patient.

The invention belongs to the biotechnology field, and discloses a glioma prognostic marker hsa_circ_0021827 and application. In the invention, it is firstly found that the expression level of hsa_circ_0021827 in the serum exosome of a glioma patient is obviously increased compared with a control group (p is equal to 0.025), and ROC analysis shows that the glioma prognostic marker hsa_circ_0021827has a relatively high diagnostic value for a glioma (AUC is equal to 0.823, P is equal to 0.003, the sensitivity is 70% and the specificity is 90.9%). Therefore, an early-stage rapid non-invasive diagnosis of the glioma patient can be made by detecting the expression level of hsa_circ_0021827 in the serum exosome of the glioma patient.

The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases.

The invention relates to primers, a kit and a system for cancer diagnosis. The primers for cancer diagnosis are PTPRO methylation specific primers. The PTPRO methylation specific primers comprise a first methylation specific primer having a sequence of 5'-GGTACGTTTTTGGAGGATTTC-3' and a second methylation specific primer having a sequence of 5'-ACGACTACGCTAACGAACTCC-3'. Through detection of a peripheral blood PTPRO gene methylation level, the primers, the kit and the system for cancer diagnosis can realize simple, convenient and accurate diagnosis of cancers.

The invention belongs to the technical field of biology and discloses a glioma diagnostic marker Circ19:5604583|5604936 and application. In the invention, exosomes secreted by normal human cells are found to have an obvious enrichment effect on the Circ19:5604583|5604936 for the first time; meanwhile, the expression level of the Circ19:5604583|5604936 in serum exosomes of glioma patients is foundto be remarkably reduced compared with that of a control group (p is equal to 0.0134); ROC (Receiver Operating Curve) analysis shows that the Circ19:5604583|5604936 has higher diagnostic value (AUC isequal to 0.928, p is smaller than 0.0001, and the sensitivity and the specificity are 100 percent and 86.2 percent respectively) to glioma. Therefore, early rapid noninvasive screening and auxiliarydiagnosis of the glioma patients can be realized by detecting the expression level of the Circ19:5604583|5604936 in the serum exosomes in people who possibly suffer from the glioma.

The invention discloses a glioma prognostic marker Circ6:4891713|4892379 and applications. The fact that the exosome secreted by glioma cells has obvious accumulation on circ6:4891713|4892379 is firstly found; the expression level of circ6:4891713|4892379 in serum exosome of patients with glioma is found to be obviously increased compared with a normal control group (p=0.0005), ROC analysis showsthat circ6:4891713|4892379 has extremely high diagnosis value on glioma (AUC=0.906, p=0.001, and sensitivity and specificity are respectively 70.8% and 100%). Therefore, the early-phase and rapid non-invasively diagnosis on the patients with glioma can be made by detecting the expression level of circ6:4891713|4892379 in serum exosome of patients with glioma.

The invention is suitable for the technical field of computers, and provides a vehicle diagnosis method and device, electronic equipment and a storage medium. The method comprises the steps of: obtaining an ECU selection instruction when a first communication link is in a connection state, and determining a target ECU; obtaining a function selection instruction, and determining a target function for the target ECU according to the function selection instruction; if the target function is a special function, destroying the first communication link; and calling a target dynamic link library corresponding to the special function, and transmitting the information of the target ECU and a target communication parameter to the target dynamic link library, so as to enable the target dynamic link library to create a second communication link according to the target communication parameter, and when the second communication link is in a connection state, executing the target function of the target ECU according to the information of the target ECU. According to the embodiment of the invention, vehicle diagnosis can be realized flexibly and conveniently.

The invention belongs to the technical field of biology and discloses a glioma diagnostic marker circ7:100812747|100813208 and application. In the invention, exosomes secreted by glioma cells are found to have an obvious enrichment effect on the circ7:100812747|100813208 for the first time; meanwhile, the expression level of the circ7:100812747|100813208 in serum exosomes of glioma patients is found to be remarkably improved compared with that of a control group (p is equal to 0.0444); ROC (Receiver Operating Curve) analysis shows that the circ7:100812747|100813208 has higher diagnostic value(AUC is equal to 0.924, p is equal to 0.001, and the sensitivity and the specificity are 83.3 percent and 87.5 percent respectively) to glioma. Therefore, early rapid noninvasive diagnosis of the glioma patients can be realized by detecting the expression level of the circ7:100812747|100813208 in the serum exosomes of the glioma patients.

The invention discloses a medical information platform capable of safely sharing information resources. The medical information platform comprises an information collection device, an information assessing module and a power source, the output end of the information collection device is connected with the input end of a data uploading module, the output end of the data uploading module is connected with the input end of a central processing module, and the output end of the central processing module is connected with the input end of a storage device. According to the medical information platform capable of safely sharing the information resources, by using the information collection device to collect pictures and video information relevant to the state of an illness of a patient, the information is comprehensively collected, so that medical personnel conveniently and comprehensively know the state of the illness of the patient, the medical personnel conveniently and precisely conduct diagnosis on the patient, the information accessing module which has a dual verification capability conducts information sharing, thus the medical information platform is safe and reliable, the safety of the privacy of the patient is guaranteed, and the service quality of a hospital is improved.

The invention belongs to the biotechnology field, and discloses a glioma prognostic marker circ17:47618350|47619164 and application. In the invention, it is firstly found that the expression level ofcirc17:47618350|47619164 in the serum exosome of a glioma patient is obviously increased compared with a control group (p is equal to 0.0218), and ROC analysis shows that the glioma prognostic markercirc17:47618350|47619164 has a relatively high diagnostic value for a glioma (AUC is equal to 0.882, P is less than 0.005, the sensitivity is 79.2% and the specificity is 100%). Therefore, an early-stage rapid non-invasive diagnosis of the glioma patient can be made by detecting the expression level of circ17:47618350|47619164 in the serum exosome of the glioma patient.

A method for monitoring track tension in construction machinery, in which data on important factors for monitoring track tension are received, is disclosed. A machine learning algorithm is performed on the basis of the data to determine the track tension state. Information about the track tension state is displayed.

The invention relates to the technical field of biological genes and particularly relates to a primer for amplifying related genes of a breast cancer and an ovarian cancer.The primer is shown by a sequence 1-36 in a sequence table.In application of the primer and a kit in amplification of the related genes of the breast cancer and the ovarian cancer, seven related genes including a coding sequence of each gene of the breast cancer and the ovarian cancer can be simultaneously detected, and the detection saves time and is efficient.A tumor paraffin-embedded tissue slice is adopted for DNA extraction, sample obtaining is easier, and sample variety is more advantageous to achievement of accurate diagnosis.The domestic self-dependently innovated kit is developed, instead of dependency on reagents / kits of foreign companies.The detection cost is remarkably reduced, and it is expected that the detection cost is reduced by 90% compared with the commercially-available prior art.

The invention belongs to the biotechnology field, and discloses a glioma prognostic marker hsa_circ_0021827 and application. In the invention, it is firstly found that the expression level of hsa_circ_0021827 in the serum exosome of a glioma patient is obviously increased compared with a control group (p is equal to 0.025), and ROC analysis shows that the glioma prognostic marker hsa_circ_0021827has a relatively high diagnostic value for a glioma (AUC is equal to 0.823, P is equal to 0.003, the sensitivity is 70% and the specificity is 90.9%). Therefore, an early-stage rapid non-invasive diagnosis of the glioma patient can be made by detecting the expression level of hsa_circ_0021827 in the serum exosome of the glioma patient.

The invention discloses a method and a device for stimulating hair cells by using acoustic signals. The method comprises the following steps: judging a frequency band corresponding to a region of damaged hair cells according to a preset algorithm; determining the frequency band corresponding to the region of the damaged hair cells as a destination frequency band; and outputting the acoustic signals with given strength to the destination frequency band so as to stimulate the region of the damaged hair cells. Therefore, hearing loss diseases can be improved by using the acoustic signals.

Provided as a technology for enabling simple and accurate diagnosis of human T-cell leukemia virus type 1 (HTLV-1) associated diseases is a method for diagnosing HTLV-1 associated diseases, the method comprising: a step for measuring, in a blood sample collected from a subject, the amount of a marker protein which is one or more selected from proteins shown in tables 1 and 2; and a step for, when the value of said measurement is not less than or not more than a predetermined reference value, determining that the subject is affected by a HTLV-1 associated disease or that remission of a HTLV-1 associated disease has occurred in the subject.

The invention belongs to the biotechnology field, and discloses a glioma prognostic marker circ1:29154696|29154910 and application. In the invention, it is firstly found that the expression level of circ1:29154696|29154910 in the serum exosome of a glioma patient is obviously increased compared with a control group (p=0.01), and ROC analysis shows that the glioma prognostic marker circ1:29154696|29154910 has a relatively high diagnostic value for a glioma (AUC=0.911, P=0.002, the sensitivity being 75% and the specificity being 98%). Therefore, an early-stage rapid non-invasive diagnosis of theglioma patient can be made by detecting the expression level of circ1:29154696|29154910 in the serum exosome of the glioma patient.

The invention belongs to the field of biological technology, and discloses a glioma diagnostic marker circ9:135881633 / 135883078, and applications thereof. According to study, it is found for the firsttime that exosome secreted by glioma possesses obvious enrichment effect on circ9:135881633 / 135883078; at the same time, it is found that the expression level of circ9:135881633 / 135883078 in serum exosome of patients with glioma is obviously higher than that of a normal reference group (P=0.0142), it is shown by ROC analysis that circ9:135881633 / 135883078 possesses relatively high diagnosis valueon glioma (AUC=0.953, P<0.001, sensitivity is 83.3%, and specificity is 96.7%). Early rapid noninvasive diagnosis on patients with glioma can be realized via measuring expression level of circ9:135881633 / 135883078 in serum exosome of patients with glioma.

The invention discloses a glioma diagnostic marker Circ6: 22020339|22020542 and an application. According to the invention, it is first found that an exosome secreted by glioma cells has an obvious enrichment effect on Circ6: 22020339|22020542, and the expression level of Circ6: 22020339|22020542 in the serum exosome of a patient who suffers from glioma is obviously reduced (p<0.0001) than that ofa control group. ROC curve analysis shows that the marker has relatively high diagnostic value (AUC=0.986, p<0.0001, the susceptibility is 100%, and the specificity is 92.9%) on glioma. Therefore, through detection of the expression level of Circ6: 22020339|22020542 in the serum exosome of a patient who suffers from glioma, noninvasive diagnosis can be early fast made to the patient who suffers from glioma.

The invention relates to a method for diagnosing faults in a high-pressure common rail system of an engine, which comprises the following steps of: breaking at least one cylinder in an engine by adopting a cylinder separation technology; measuring the rail pressure in the high-pressure common rail system after cylinder breakage on the basis of a crankshaft rotating angle; filtering practical rail pressure measured in real time to form input rail pressure; sampling the input rail pressure at a predefined crankshaft rotating angle interval to form a sampling signal; selecting the sampling signal positioned in a rail pressure stable area of the high-pressure common rail system as a characteristic sampling point of rail pressure; filtering the characteristic sampling point to generate rail pressure obtained after cylinder breakage; solving a rail pressure difference value of the rail pressure obtained after cylinder breakage and factory rail pressure; and when the difference value is higher than a preset threshold value, judging that the high-pressure common rail system has a fault. The method also comprises the step of compensating oil spray amount and oil pumping amount which are associated with the rail pressure difference value into the factory oil spray amount and oil pumping amount if the high-pressure common rail system has the fault so as to calibrate the fault.

The invention belongs to the biotechnology field, and discloses a glioma prognostic marker circ7:73686636|73687095 and application. In the invention, it is firstly found that the expression level of circ7:73686636|73687095 in the serum exosome of a glioma patient is obviously increased compared with a control group (p is equal to 0.0012), and ROC analysis shows that the glioma prognostic marker circ7:73686636|73687095 has a relatively high diagnostic value for a glioma (AUC is equal to 0.872, P is equal to 0.001, the sensitivity is 76.5% and the specificity is 90.9%). Therefore, an early-stagerapid non-invasive diagnosis of the glioma patient can be made by detecting the expression level of circ7:73686636|73687095 in the serum exosome of the glioma patient.

The invention discloses an X-ray opaque marker barium sulfate pellet, which comprises a pellet core, a barium sulfate wrapping layer and a coating layer. The particle size of the barium sulfate pelletis 6-7 meshes. The pellet core includes barium sulfate, filler and a binder. The barium sulfate wrapping layer comprises feed powder containing barium sulfate and a diluent, and an adhesive, the feedpowder is attached to or wrapped on the outer layer of the pellet core, and the coating layer includes a sustained-release material. The invention also provides a preparation method and use of the barium sulfate pellet. When applied to colonic transit test for diagnose of constipation disease type, the barium sulfate pellet disclosed by the invention has good stability and good clear developmenteffect, improves the accuracy of the colonic transit test result, is conducive to accurate diagnosis of the constipation disease type, improves the matching accuracy of follow-up treatment methods forpatients, and reduces the patient's pain of delayed disease treatment caused by diagnostic errors. The preparation method of the barium sulfate pellet disclosed by the invention has the advantages ofsimplicity, easy operation, safety and environmental protection, and is conducive to realizing industrial expanded production.

The invention discloses a glioma diagnostic marker Circ2: 23823258|23823569 and an application. According to the invention, it is first found that an exosome secreted by glioma cells has an obvious enrichment effect on Circ2: 23823258|23823569, and the expression level of Circ2: 23823258|23823569 in the serum exosome of a patient who suffers from glioma is obviously improved (p<0.0001) than that of a control group. ROC curve analysis shows that the marker has relatively high diagnostic value (AUC=0.811, p=0.002, the susceptibility is 66.7%, and the specificity is 91.7%) on glioma. Therefore, through detection of the expression level of Circ2: 23823258|23823569 in the serum exosome of a patient who suffers from glioma, noninvasive diagnosis can be early fast made to the patient who suffersfrom glioma.